计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 6 篇同行评审文献引用。
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products ( AGEs ), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .
In Vitro
3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300 ng/ml or 1000 ng/ml 3DG-treated group. But at alower concentration (80 ng/ml) has no effects. 3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca 2+ levels by Fluo-3/AM determination (2.5 μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay. 3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: STC-1 cells Concentration: 300 ng/ml Incubation Time: 1 hour Result: Upregulated TAS1R2, TAS1R3, and TRPM5 expression.
In Vivo
3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose) impairs glucose tolerance with increased AUC, but the plasma Glukagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats. 3-deoxyglucosone (gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SD ratsDosage: 5, 20 and 50 mg/kg Administration: oral administration; once daily; 2 weeks Result: Was capable of accumulating in intestinal tissue and thereby decreased secretion of GLP-1 and insulin.
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 脂质和脂质样分子 |
| 类(Class) | 脂肪酰基 |
| 亚类(Subclass) | 脂肪醇 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 脂肪醇 |
| 其他上位类(Alternative Parents) | 中链醛 β-羟基酮 α-酮醛 仲醇 多元醇 伯醇 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 脂肪族无环化合物 |
| 取代基(Substituents) | 羟基苯甲酸酯 - 醛 - 脂肪族非环化合物 - α-羰基醛 - β-羟基酮 - 羰基 - 脂肪醇 - 烃衍生物 - 酮 - 中链醛 - 有机氧化物 - 有机氧化合物 - 有机氧化合物 - 多醇 - 初级醇 - 醛基 |
| 描述(Description) | 该化合物属于有机化合物中的脂肪醇类。这类化合物是含至少六个碳原子的烷基醇。 |
| 外部描述符(External Descriptors) | deoxyketohexose - deoxyglucose |
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P264: 处理后要彻底洗手。
P271: 仅在室外或通风良好的地方使用。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P321: 特殊处理(请参阅此标签上的...)。
P302+P352: 如皮肤沾染:用水充分清洗。
P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。
P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。
P405: 密闭存放
P403+P233: 存放在通风良好的地方。保持容器密闭。
P501: 将内容物/容器处理到。。。
P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。
P337+P317: 如果眼睛刺激持续:寻求医疗帮助。
P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。
P319: 如果你感到不适,请寻求医疗帮助。